NIH-funded research R01 grant

How liver inflammation may change drinking through the hormone FGF21

Official title: Identifying an immunoregulatory axis for FGF21 in alcohol consumption

Funded at Ut Southwestern Medical Center · NIH-11195681 · Data updated 2026-11-12

This project looks at whether liver inflammation cuts levels of the hormone FGF21 and in turn makes people drink more and worsens alcohol-related liver disease.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUt Southwestern Medical Center
NIH-funded
Lab location1 site (Dallas, United States)
Project startSeptember 20, 2024
Project endJune 30, 2029
Funding year2025
Award (this year)$537,587
NIH project number5R01AA031460-02
Project IDNIH-11195681 on NIH RePORTER

Who could benefit from this research

Could help

People with alcohol use disorder or alcohol-associated liver disease, especially those with ongoing heavy drinking, would be the most relevant candidates.

Less likely to help

People whose liver problems are unrelated to alcohol or those with distant, resolved alcohol use are unlikely to benefit from this work.

What this research studies

From my point of view as a patient, the researchers are trying to understand a liver-to-brain signal that could influence alcohol craving and liver damage. They will use lab models to change a liver immune switch called IRF3 and its target PLAGL1 to see how those changes affect FGF21 production. The team will link those molecular changes to alcohol drinking behavior and signs of liver injury, mostly in controlled lab experiments that mimic alcoholic liver disease. If restoring FGF21 or blocking the inflammatory signal lowers drinking or protects the liver in these models, it could point to new treatment approaches.

Why it matters

Potential benefit: If successful, this work could point to new treatments that boost FGF21 or block the inflammatory pathway to reduce heavy drinking and protect the liver.

How similar studies have gone: Previous animal and some human genetic studies suggest FGF21 can influence alcohol intake, but targeting the IRF3–PLAGL1 inflammatory pathway is a newer approach.

Where this research is happening

  • Ut Southwestern Medical Center
    Dallas, United States
    Active

Researchers

  • Principal investigator: Patel, Suraj J — Ut Southwestern Medical Center
  • Study coordinator: Patel, Suraj J

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.